Targeted therapy in high grade serous ovarian Cancer

Ovarian cancer's high mortality persists despite advances. Platinum-based chemotherapy faces resistance, pushing for targeted therapies like PARP inhibitors and anti-angiogenic agents. Emerging targets include tyrosine kinase inhibitors and gene therapy, under investigation from preclinical to phase III trials.